UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.
Researchers at Hiroshima University and international collaborators discovered that hyperactive YAP and TAZ proteins, which promote cancer, are associated with genomic instability that enables tumor cells to evade immune system detection and destruction.
New research published in Cancer Cell reveals that glioblastoma patients have more active platelets, which are blood clotting cells that also communicate with other cells and influence immune activity. The findings suggest platelets may play an unexpected role in the progression of this aggressive brain cancer.
Researchers at Roswell Park Comprehensive Cancer Center have discovered that hormone-blocking therapies commonly used to treat prostate cancer temporarily activate the body's immune response, revealing a critical window for boosting immunotherapy effectiveness.
Preclinical research demonstrates that macrophages can be programmed to fight solid cancer tumors, offering a potential new immunotherapy approach. The development comes as cancer kills one person every 50 seconds in the U.S., with some cancers continuing to resist current treatments.
Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.
The FDA has granted accelerated approval to dostarlimab-gxly (Jemperli) as monotherapy for adults with previously untreated stage II or III locally advanced rectal cancer with dMMR or MSI-H status, based on interim phase 2 AZUR-1 trial results. This marks a first-in-class approval in this specific type of rectal cancer.
Vir Biotechnology signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop T cell engager treatments for solid tumors, with Gilead paying $65 million upfront and $45 million in near-term milestones.
Merck CEO Rob Davis said he expects the personalized cancer vaccine being developed with Moderna to have a shortened production timeline from its current six-week manufacturing period. The announcement comes after the companies reported promising late-stage trial results in August for the mRNA vaccine combined with immunotherapy for melanoma.
An international multidisciplinary group of 31 experts coordinated by EBMT, ISCT, and JACIE has released updated consensus recommendations for using CAR T-cell therapy in patients with severe, treatment-refractory autoimmune diseases. The guidelines, originally released in 2024, include recommendations around optimizing safety.
Adicet Bio reported positive early trial results for prula-cel, an off-the-shelf gamma delta CAR-T therapy for systemic lupus erythematosus. At 12 months, 54% of evaluable patients achieved DORIS remission with no severe side effects, surpassing benchmarks set by personalized CAR-T treatments.
First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.
Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.
The IMpower030 trial showed that adding perioperative atezolizumab to platinum-based chemotherapy nearly doubled median event-free survival in patients with stage IIB-IIIB resectable non-small cell lung cancer without EGFR mutations, but the drug missed its primary endpoint.
AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.
Innovent Biologics has initiated a registrational phase 3 study evaluating IBI363, a PD-1/IL-2α bispecific fusion protein, combined with bevacizumab in 550 patients with treatment-refractory colorectal cancer.
An international study led by Mayo Clinic researchers has identified interleukin-6 (IL-6) receptor blockers as a promising therapy for preventing relapses in myelin oligodendrocyte glycoprotein antibody-associated disease, a rare neurological condition.
Engineered silica nanoparticles caused prostate cancer tumor cells to self-destruct and activated immune response in preclinical mouse studies. Combined with immunotherapy, the treatment showed promising results against aggressive disease.
The FDA approved sacituzumab govitecan-hziy (Trodelvy) on June 24, 2026, for two indications in adults with triple-negative breast cancer: as monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of advanced disease, offering new options beyond standard chemotherapy.
The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.
Ivonescimab, an experimental drug combining two immunotherapy mechanisms, reduced the risk of death by 34% compared to standard immunotherapy in patients with advanced squamous non-small cell lung cancer in a closely watched Chinese trial. The drug helped patients live 15% longer than BeOne Medicines' Tevimbra.
AstraZeneca's VOLGA trial confirms that the Imfinzi EV combination significantly improves overall survival for cisplatin-ineligible bladder cancer patients, representing a major advancement in treatment for this difficult-to-treat population.
Early trial results presented at AACR show CAR-T cell therapy may prevent smoldering multiple myeloma from progressing to active disease in high-risk patients, representing a potential preventive approach to cancer treatment.